MicroRNAs miR-16 and miR-519 control meningioma cell proliferation overlapping transcriptomic programs shared with the RNA-binding protein HuR.

Date publication

août 2023

Journal

Frontiers in oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GUEANT Jean-Louis , Dr HOULGATTE Rémy , Pr VIGNAUD Jean-Michel , Pr GAUCHOTTE Guillaume , Dr OUSSALAH Abderrahim , Dr BATTAGLIA-HSU Shyue-Fang , Dr RECH Fabien

Tous les auteurs :
Hergalant S, Casse JM, Oussalah A, Houlgatte R, Helle D, Rech F, Vallar L, Guéant JL, Vignaud JM, Battaglia-Hsu SF, Gauchotte G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37601663

Résumé

Meningiomas are the most common type of primary central nervous system tumors. In about 80% cases, these tumors are benign and grow very slowly, but the remainder 20% can unlock higher proliferation rates and become malignant. In this study we examined two miRs, miR-16 and miR-519, and evaluated their role in tumorigenesis and cell growth in human meningioma.

Mots clés

HuR, meningioma, miR-16, miR-519, microRNA, proliferation, transcriptomics, tumorigenesis

Référence

Front Oncol. 2023 08 2;13:1158773